Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)

  title={Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)},
  author={Kumar B Rajan and Jennifer Weuve and Lisa L. Barnes and Elizabeth A McAninch and Robert S. Wilson and Denis A. Evans},
  journal={Alzheimer's \& Dementia},
  pages={1966 - 1975}
  • K. Rajan, J. Weuve, +3 authors Denis A. Evans
  • Published 27 May 2021
  • Medicine
  • Alzheimer's & Dementia
The estimate of people with clinical Alzheimer's disease (AD) and mild cognitive impairment provides an understanding of the disease burden. 
13 Citations
Alzheimers's disease: Epidemiological characteristics and its prevention
It is estimated that by reducing the modifiable risk factors, 40% of cases of Alzheimer's dementia can be prevented or postponed, and it is important to raise awareness of available screening methods for early detection of Alzheimer't disease and prevention opportunities.
Network activity changes in the pathophysiology of Alzheimer's disease: the role of aging and early entorhinal cortex dysfunction.
Evidence in the literature is described how one potential age-related change, that of glutamate-mediated increases in neuronal activity, may ultimately increase the risk of developing AD and promote the spread of tau pathology in AD-affected brains from the EC to later regions such as the hippocampus and prefrontal cortex.
Olfactory Measures as Predictors of Conversion to Mild Cognitive Impairment and Alzheimer’s Disease
Background: Early biomarkers of prodromal Alzheimer’s disease (AD) are critical both to initiate interventions and to choose participants for clinical trials. Odor threshold, odor identification and
Heart health meets cognitive health: evidence on the role of blood pressure
Long-term interventional and observational studies in ethnically and racially diverse populations, with novel imaging and blood-based biomarkers of neurodegeneration and vascular cognitive impairment to understand the pathophysiology, are needed to advance the field.
Effectiveness of home-based electronic cognitive therapy in patients with Alzheimer’s disease dementia: A Feasibility Study (Preprint)
BACKGROUND Can home-based computerized cognitive training programs be a useful tool to sustain cognition and quality of life in patients with Alzheimer’s disease (AD) dementia? Until now, the
Symptomatic, Genetic, and Mechanistic Overlaps between Autism and Alzheimer’s Disease
Autism spectrum disorder (ASD) and Alzheimer’s disease (AD) are neurodevelopmental and neurodegenerative disorders affecting two opposite ends of life span, i.e., childhood and old age. Both
Magnesium valproate adjuvant therapy on patients with dementia
  • Chen qi Zhang, ke xin Zheng, Ling qi Sun, Hongbin Sun
  • Medicine
  • 2021
VPM maybe plays an active role in the treatment of dementia patients and this research will provide reliable evidence for clinicians in therapy of PwD.
Baby Boomers Who Provide Informal Care for People Living with Dementia in the Community
The prevalence of Baby Boomers who are informal caregivers for people living with dementia and compare their physical and mental health status to caregivers for persons with conditions other than dementia using 2015–2018 Behavioral Risk Factor Surveillance System data is estimated.
Serum Glycoproteomics and Identification of Potential Mechanisms Underlying Alzheimer's Disease
Objectives This study compares glycoproteomes in Thai Alzheimer's disease (AD) patients with those of cognitively normal individuals. Methods Study participants included outpatients with clinically
Alterations in T-Cell Transcription Factors and Cytokine Gene Expression in Late-Onset Alzheimer’s Disease
Background: Late-onset Alzheimer’s disease (LOAD) is associated with many environmental and genetic factors. The effect of systemic inflammation on the pathogenesis of neurodegenerative diseases such


Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States
We forecast the prevalence of preclinical and clinical Alzheimer's disease (AD) and evaluated potential impacts of primary and secondary preventions in the United States.
The worldwide costs of dementia 2015 and comparisons with 2010
In 2010, Alzheimer's Disease International presented estimates of the global cost of illness (COI) of dementia. Since then, new studies have been conducted, and the number of people with dementia has
Direct medical costs and source of cost differences across the spectrum of cognitive decline: A population-based study
Objective cost estimates and source of cost differences are needed across the spectrum of cognition, including cognitively normal (CN), mild cognitive impairment (MCI), newly discovered dementia, and
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
Article abstract-Clinical criteria for the diagnosis of Alzheimer’s disease include insidious onset and progressive impairment of memory and other cognitive functions. There are no motor, sensory, or
Age-specific incidence of Alzheimer's disease in a community population.
The incidence of Alzheimer's disease is substantial and is approximately 14 times higher among persons older than 85 years compared with those between 65 and 69 years of age.
Prevalence of dementia in a southern European population in two different time periods: the ZARADEMP Project
The prevalence of dementia in two different time periods and two different studies is compared to find out whether the disease is more common in adults over a longer period of time or a shorter time period.
Trends in the incidence and prevalence of Alzheimer’s disease, dementia, and cognitive impairment in the United States
Although some decline was observed in the Minnesota cohort, no statistically significant trends were apparent in the community studies, and a significant reduction in cognitive impairment measured by neuropsychological testing was identified in the national survey.
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
The number of people in the United States with AD dementia will increase dramatically in the next 40 years unless preventive measures are developed.
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available.
Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease.
The results showed that the EBMT was better at enriching the population of the poor performance group with persons who had Alzheimer's disease (AD), and had a lower refusal rate among non-proxy respondents than the SPMSQ.